Personalised Medicine for Morbid Obesity

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2012 by Imperial College London
Information provided by (Responsible Party):
Imperial College London Identifier:
First received: June 1, 2011
Last updated: June 3, 2015
Last verified: October 2012

The prevalence of morbid obesity (BMI > 40 kg/m2) is increasing rapidly in the UK, but the investigators lack a coherent strategy for detailed assessment and treatment of the individuals affected, who are at high risk of morbidity and early mortality. The investigators already know that more than 1 in 20 severely-obese individuals have a simple genetic cause of their obesity (usually inherited in an autosomal dominant pattern. Bariatric surgery is the most effective treatment for morbid obesity and certain surgeries can result in the remission of type 2 diabetes. However, some patient fail to achieve the weight loss or experience complications and re-operations. The investigators are unable to predict the outcomes of bariatric surgery particularly in relation to type 2 diabetes remission which is crucial for the assessment of risk to benefit balance before wider future applications of the surgery.

The investigators want to investigate the mechanism underlying Type 2 diabetes remission after bariatric surgery by A) examining the effect of Mendelian forms of obesity and diabetes on T2D remission, B) studying changes in expression profiling patterns in insulin-responsive tissues, C) identifying of eQTLs, and of other genetic variations affecting T2D remission and D) studying the role of epigenetic variation in T2D remission.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Genetic Analysis for Personalised Medicine for Morbid Obesity

Further study details as provided by Imperial College London:

Biospecimen Retention:   Samples With DNA
SALIVA BLOOD URINE AND FAECES TISSUE (Muscle, Liver, Subcutaneous fat, Visceral fat)

Estimated Enrollment: 2000
Study Start Date: November 2011
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
2000 obese patients

Inclusion Criteria:

  • BMI >28 kg/m2
  • Age between 18-65 years

Exclusion Criteria:

  • donation of blood within the last 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01365416

Contact: Alexandra I Blakemore, Reader 020 7594 6511 ext 45511
Contact: Christina G Prechtl, PhD 020 33 13 0532 ext 30532

United Kingdom
Imperial Weight Centre Recruiting
London, United Kingdom
Contact: Christina Prechtl, PhD    02083835970   
Sub-Investigator: Christina Prechtl, PhD         
Sponsors and Collaborators
Imperial College London
Principal Investigator: Alexandra I Blakemore, Prof Imperial College London
  More Information

No publications provided

Responsible Party: Imperial College London Identifier: NCT01365416     History of Changes
Other Study ID Numbers: PMMO
Study First Received: June 1, 2011
Last Updated: June 3, 2015
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
diabetes remission
bariatric surgery
gene expression
genetic variation
epigenetic variation

Additional relevant MeSH terms:
Obesity, Morbid
Body Weight
Nutrition Disorders
Signs and Symptoms processed this record on November 25, 2015